


Suggested Clinical Workflow for Screening and Imaging: Integrating AJCC Staging and Gene Expression Profiling



Notes— Adverse features resulting in microstaging uncertainty in Stage IA melanomas for the purposes of SLNB consideration include features such as positive deep margin, mitosis, lymphovascular invasion, mitotic rate >1mm², regression, perineural invasion, and a Class 2 31-GEP test result. Stage III is not broken into sub-stages as the focus of the clinical impact is on Stage IIIa. Stage IV is not included because 31-GEP test is not clinically helpful to predict metastasis when it has already been detected.

Key—AJCC: American Joint Commission on Cancer; FP: false positive; GEP: gene expression profiling; SLNB: sentinel lymph node biopsy; N/A: not applicable; NCCN: National Comprehensive Cancer Network